The current state of cancer therapeutics has been moving away from one-size-fits-all cytotoxic chemotherapy, and towards a more individualized and specific approach involving the targeting of each tumor's genetic vulnerabilities. Different tumors, even of the same type, may be more reliant on certain cellular pathways more than others. With modern advancements in our understanding of cancer genome sequencing, these pathways can be discovered. Investigating each of the millions of possible small molecule inhibitors for each kinase in vitro, however, would be extremely expensive and time consuming. This project focuses on predicting the inhibition activity of small molecules targeting 8 different kinases using multiple deep learning models. We trained fingerprint-based MLPs and simplified molecular-input line-entry specification (SMILES)-based recurrent neural networks (RNNs) and molecular graph convolutional networks (GCNs) to accurately predict inhibitory activity targeting these 8 kinases.
We introduce Adam, an algorithm for first-order gradient-based optimization of stochastic objective functions, based on adaptive estimates of lower-order moments. The method is straightforward to implement, is computationally efficient, has little memory requirements, is invariant to diagonal rescaling of the gradients, and is well suited for problems that are large in terms of data and or parameters. The method is also appropriate for non-stationary objectives and problems with very noisy and or sparse gradients. The hyper-parameters have intuitive interpretations and typically require little tuning. Some connections to related algorithms, on which Adam was inspired, are discussed. We also analyze the theoretical convergence properties of the algorithm and provide a regret bound on the convergence rate that is comparable to the best known results under the online convex optimization framework. Empirical results demonstrate that Adam works well in practice and compares favorably to other stochastic optimization methods. Finally, we discuss AdaMax, a variant of Adam based on the infinity norm.